Podcast
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Hosted by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · EN
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology.
Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com.
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com.
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
35episodes
Episodes
Newest firstAll episodes
Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS
Jun 800:23:44Tap to summarizeWelcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx
Transcribe →
The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD
Jun 600:24:40Tap to summarizeWelcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded on-site at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Dr. Eugene Wright Jr., MD, the principal of Wright Health Care Solutions and a consulting associate in the department of medicine at Duke University Medical Center, to discuss the development of the ADA scientific statement on diabetes technology implementation in primary care. To begin the episode, Wright reflects on his career as an internist caring for patients with diabetes across diverse settings, including underserved communities where patients often faced significant barriers to accessing care. He describes how his experiences challenged assumptions about which patients would benefit from diabetes technology, noting that many under-resourced patients demonstrated strong engagement and improved self-management when given access to tools such as continuous glucose monitoring (CGM).The discussion focuses on the origins of the ADA scientific statement, which emerged from efforts to identify and overcome barriers limiting the adoption of diabetes technology in primary care. Wright explains that while diabetes technology has demonstrated significant benefits in improving outcomes and patient behaviors, implementation has remained slow in the settings where most people with diabetes receive care. The statement brought together key stakeholders, including clinicians, pharmacists, diabetes care and education specialists, patient representatives, and other experts, to develop practical strategies addressing policy, insurance, workflow, and clinical challenges.Isaacs, Bellini, and Wright explore how CGM can be successfully integrated into primary care by shifting the focus from simply providing access to using data effectively. Wright emphasizes that CGM and ambulatory glucose profile (AGP) reports allow clinicians to transform complex glucose data into actionable insights, helping identify patterns that may not be captured through A1C measurements or traditional glucose monitoring. The group discusses how CGM enables clinicians to ask better questions, uncover barriers to treatment, and engage patients in collaborative conversations without judgment.The hosts highlight the importance of building sustainable workflows, including preparing AGP reports before visits, assigning responsibilities across the care team, and identifying technology champions within practices. Wright explains that successful implementation requires recognizing the unique needs and resources of each primary care setting rather than applying a single model. They discuss the role of telehealth, clinical pharmacists, medical assistants, and other team members in supporting CGM initiation, interpretation, and ongoing management. The conversation also addresses how partnerships with technology manufacturers can simplify onboarding, training, troubleshooting, and patient support.The discussion then expands to insulin pumps and automated insulin delivery systems, with the group noting how advances in technology have reduced complexity and made these therapies more accessible for people with type 2 diabetes. Wright describes how newer systems can help reduce the daily burden of diabetes management by automating adjustments and supporting patients in achieving their goals. The hosts emphasize that diabetes care should move beyond focusing only on glucose metrics and instead consider the lived experience of patients, including the constant decision-making and emotional burden associated with managing diabetes.The episode concludes with a broader call to action for expanding access to diabetes technology across all healthcare settings. Wright emphasizes that many patients do not have access to endocrinology care but still deserve the benefits of modern diabetes tools. The scientific statement represents the beginning of an ongoing effort to improve implementation, strengthen collaboration among stakeholders, and ensure that diabetes technology reaches all patients who can benefit from it.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Wright Jr. reports disclosures with Abbott Diabetes, Bayer AG, Boehringer Ingelheim, Lilly, and Sanofi.ReferencesSection 7: Diabetes technology. Diabetes Obesity and Cardiometabolic CARE. Published online March 23, 2026. doi:10.2337/doc26-a007
Transcribe →
Diabetes Dialogue: AACE 2025 Recap
May 26, 2025Tap to summarizeVideo Version Only on HCPLive!In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, co-hosts Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES, and Natalie Bellini, DNP, FNP-BC, provide a comprehensive review of the 2025 American Association of Clinical Endocrinology (AACE) Annual Meeting held in Orlando, Florida. The episode captures notable sessions, emerging clinical insights, and advances in diabetes care and endocrinology presented during the conference.The discussion opens with reflections on keynote lectures, including a plenary led by Daniel Drucker, MD, on incretin physiology and the clinical evolution of GLP-1 receptor agonists. Isaacs highlights the importance of his translational research and addresses the implications of safety concerns such as pancreatitis and thyroid cancer. Both hosts express admiration for Drucker’s role in shaping the field of incretin-based therapies.Another highlight includes the plenary delivered by Anne L. Peters, MD, which emphasized health equity and expanding access to diabetes technology in underserved populations. Isaacs discusses Peters’ innovative use of pharmacists in insulin pump clinics and her longstanding contributions to ADA standards of care. Bellini commends Peters' dual impact in both affluent and marginalized communities.The hosts also describe their participation in a hands-on diabetes technology workshop, where attendees rotated through device-specific stations including insulin pumps, CGMs, inhaled insulin, and smart pens. This workshop was part of a broader effort to launch a diabetes technology certification program, with both in-person and online components scheduled for release in summer 2025.Clinical trial updates included coverage of the CONTROL-IQ Plus RCT in type 2 diabetes, studies on weekly insulin formulations, CGM use in inpatient settings, and the Inhale-3 trial on inhaled insulin efficacy. Discussions also touched on advancements in over-the-counter CGMs, data interpretation challenges in individuals without diabetes, and the proposed shift toward using time-in-normal glucose range (TING) metrics to assess glycemic control.The episode concludes with enthusiasm for the future of patient-centered technology and anticipation for the AACE 2026 meeting in Las Vegas.Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.
Transcribe →Diabetes Dialogue: 2023 Top Episodes Recap
Jan 1, 2024Tap to summarizeTo celebrate the end of 2023, hosts recap the top 10 episodes of the past year and offer perspective on how the news discussed in these episodes has shaped the future of diabetes management. Episode Highlights00:32 Automated Insulin Delivery News in October 202304:35 Breaking Down AACE's New Type 2 Diabetes Management Algorithms06:45 What Medicare Drug Price Negotiations Mean for Diabetes 09:15 STEP-HFpEF Reaction 12:10 Dexcom G7 and the Future of CGM, with Jake Leach13:20 Tandem Mobi and Welldoc's BlueStar Platform16:20 Making Sense of Semaglutide in Type 1 Diabetes18:35 Establishing Time in Range as a Primary Glucose Metric21:15 TRANSITION-T2D, with Paloma Rodriguez, MD, and Kevin Pantalone, DO 25:15 What to Know about the iLet Bionic Pancreas
Transcribe →Diabetes Dialogue: ADCES 2023 Recap
Aug 23, 2023Tap to summarizeIn this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th-anniversary celebration.Video version: https://www.hcplive.com/view/diabetes-dialogue-adces-2023-recap
Transcribe →Diabetes Dialogue: ADA 2023 Recap
Aug 23, 2023Tap to summarizeAfter a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.Video version: https://www.hcplive.com/view/diabetes-dialogue-ada-2023-recap
Transcribe →Diabetes Dialogue: TRANSITION-T2D, with Paloma Rodriguez, MD, and Kevin Pantalone, DO
Aug 23, 2023Tap to summarizeInvestigators from the TRANSITION-T2D study join Diabetes Dialogue to discuss the study and implications for care.Video version: https://www.hcplive.com/view/diabetes-dialogue-transition-t2d
Transcribe →
Diabetes Dialogue: Managing & Addressing Mental Health Needs in Diabetes
Aug 23, 2023Tap to summarizeOften overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.Video version: https://www.hcplive.com/view/diabetes-dialogue-managing-addressing-mental-health-needs-in-diabetes
Transcribe →Diabetes Dialogue: ATTD 2023 Recap
Mar 3, 2023Tap to summarizeA recap of the top news and research from the 16th annual meeting for Advanced Technologies and Treatments for Diabetes in Berlin, Germany.
Transcribe →Diabetes Dialogue: The Role of Patient Voice in Diabetes Management
Feb 28, 2023Tap to summarizeIn this episode, hosts are joined by Marissa Town, BSN, RN, and Renza Scibilia for a discussion centered around the role of the patient voice in diabetes management while on site at ATTD 2023.
Transcribe →